Pacira BioSciences, Inc. (PCRX)
NASDAQ: PCRX · Real-Time Price · USD
25.22
+0.05 (0.22%)
At close: Sep 11, 2026, 4:00 PM EDT
25.36
+0.14 (0.58%)
After-hours: Sep 11, 2026, 7:30 PM EDT
Pacira BioSciences Stock Forecast
Stock Price Forecast
According to 8 analysts polled by S&P Global, Pacira BioSciences stock has a consensus rating of "Buy" and an average price target of $29.75. The average 1-year stock price forecast is 17.99% higher than the current stock price, while the lowest is $23 (-8.78%) and the highest is $38 (+50.70%).
Price Target: $29.75 (+17.99%)
Analyst Consensus: Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Pacira BioSciences stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Apr '26 | May '26 | Jun '26 | Jul '26 | Aug '26 | Sep '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 2 | 2 | 3 | 3 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 2 | 2 | 2 | 2 | 2 | 3 |
| Sell | 1 | 1 | 1 | 1 | 1 | 1 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 7 | 6 | 6 | 7 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Leerink Partners | Leerink Partners | Hold Initiates $28 | Hold | Initiates | $28 | +11.05% | Sep 9, 2026 |
| Truist Financial No rating | Truist Financial | Buy Maintains n/a | Buy | Maintains | n/a | n/a | Aug 24, 2026 |
| Barclays | Barclays | Hold Maintains $25 | Hold | Maintains | $25 | -0.85% | Aug 17, 2026 |
| J.P. Morgan | J.P. Morgan | Sell Maintains $23 | Sell | Maintains | $23 | -8.78% | Aug 10, 2026 |
| H.C. Wainwright | H.C. Wainwright | Buy Reiterates $38 | Buy | Reiterates | $38 | +50.70% | Aug 5, 2026 |
Financial Forecast
Revenue This Year
753.72M
from 726.41M
Increased by 3.76%
Revenue Next Year
788.71M
from 753.72M
Increased by 4.64%
EPS This Year
2.89
from 2.65
Increased by 9.03%
EPS Next Year
3.44
from 2.89
Increased by 18.98%
EPS and Forward PE are based on non-GAAP adjusted numbers.